Cardiff Oncology

Filed a patent for "inhibition of hypoxia signaling pathway by plk1 inhibitor" on Tue, August 1, 2023

Filed a patent for "inhibition of hypoxia signaling pathway by plk1 inhibitor" on Mon, March 4, 2024

Filed a patent for "inhibition of hypoxia signaling pathway by plk1 inhibitor" on Fri, April 5, 2024

Filed a patent for "cancer treatment using lsd1 inhibitors and plk1 inhibitors" on Tue, May 14, 2024

Filed a patent for "onvansertib parp inhibitor combination" on Thu, September 8, 2022

Filed a patent for "irinotecan sensitization with onvansertib" on Thu, September 8, 2022

Filed a patent for "prediction of clinical benefit with kras mutant allele frequency" on Thu, September 8, 2022

Filed a patent for "cancer treatment using mtdp inhibitors and plk1 inhibitors" on Fri, September 9, 2022

Filed a patent for "plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer" on Sun, September 11, 2022

Filed a patent for "cancer treatment using fgfr inhibitors and plk1 inhibitors" on Thu, April 20, 2023

Filed a patent for "predictive biomarkers for onvansertib treatment" on Thu, June 15, 2023

Filed a patent for "methods of monitoring kras mutations" on Thu, June 8, 2023

Filed a patent for "plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer" on Wed, July 26, 2023

Filed a patent for "cancer treatment using parp inhibitors and plk1 inhibitors" on Thu, June 20, 2024

Filed a patent for "plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer" on Thu, March 28, 2024

Filed a patent for "cancer treatment using parp inhibitors and plk1 inhibitors" on Tue, March 22, 2022

Filed a patent for "irinotecan sensitization with onvansertib" on Tue, May 31, 2022

Filed a patent for "circulating tumor dna as a biomarker for leukemia treatment" on Thu, June 1, 2023

Filed a patent for "treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitors" on Thu, April 13, 2023